Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | NA |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | 2 | ||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR etc |
| Sample | cell lines(LNCaP-AR+) |
| Expression Pattern | up-regulated |
| Function Description | H19 expression in cells treated with DHT and enzalutamide was 2.5-fold higher than that in control cells and 5-fold higher than in cells stimulated with DHT (p < 0.05) (Fig. 1). |
| Pubmed ID | 32356434 |
| Year | 2020 |
| Title | Investigation of lncRNA H19 in prostate cancer cells and secreted exosomes upon androgen stimulation or androgen receptor blockage. |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |